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Strengths and limitations of this study
 ► Selection of an evidence- based approach and ad-
aptation of the intervention was based on extensive 
formative research with pregnant Pakistani women 
and their providers.
 ► A strength of the design includes the exclusion of 
women who are prenatally depressed, which will 
allow us to isolate the effects of prevention of symp-
toms of anxiety.
 ► A challenge in study implementation includes the 
continued participation of women through the com-
pletion of the intervention and to the final assess-
ment point at 6- week postpartum.
 ► Given the hospital- based nature of this study, par-
ticipants do not necessarily represent all women of 
reproductive age with anxiety, such as rural or other 
women who tend to give birth at home.
AbStrACt
Introduction Prenatal anxiety is a prevalent condition that 
is harmful for women and a strong predictor of postpartum 
depression. This trial assesses an intervention initiated 
in early pregnancy to mid pregnancy among women with 
clinical or subclinical symptoms of anxiety in Pakistan.
Methods and analysis Happy Mother, Healthy Baby 
(HMHB) is a phase three, two- arm, single- blind, individual 
randomised clinical trial conducted in the outpatient 
department of Holy Family Hospital, a large public tertiary 
care facility affiliated with Rawalpindi Medical University 
(RMU). Pregnant women (enrolled at ≤22 weeks of 
gestation) receive six individual HMHB sessions based 
on cognitive–behavioral therapy (CBT) and relaxation 
techniques that are administered by non- specialist 
providers and tailored to address anxiety symptoms. 
Two to six booster sessions are given between the fifth 
consecutive weekly core session and the sixth core 
session that occurs in the third trimester. Apart from 
baseline data, data are collected in the third trimester, 
at birth and at 6- weeks postpartum. Primary outcomes 
include diagnoses of postpartum common mental 
disorders. Secondary outcomes include symptoms of 
anxiety and of depression, and birth outcomes including 
small- for- gestational age, low birth weight and preterm 
birth. An economic analysis will determine the cost 
effectiveness of the intervention.
Ethics Ethics approval was obtained from the Johns 
Hopkins Bloomberg School of Health Institutional Review 
Board (Baltimore, USA), the Human Development Research 
Foundation Ethics Committee (Islamabad, Pakistan), the 
RMU Institutional Research Forum (Rawalpindi, Pakistan) 
and the National Institute of Mental Health- appointed 
Global Mental Health Data Safety and Monitoring Board.
Dissemination Results from this trial will build 
evidence for the efficacy of a CBT- based intervention for 
pregnant women delivered by non- specialised providers. 
Identification of an evidence- based intervention for anxiety 
starting in early pregnancy to mid pregnancy may be 
transferable for use and scale- up in other low- income and 
middle- income countries.
trial registration number NCT03880032.
IntroDuCtIon
Pregnant women frequently suffer from 
common mental health disorders (CMDs) 
such as anxiety and depression.1 In low/
middle- income countries (LMICs), women 
are particularly predisposed to CMDs, and 
these disorders are associated with risk factors 
such as gender discrimination, interpersonal 
violence, lack of support, poverty and poor 
health.2 In Pakistan, 35%3–49%4 of pregnant 
women suffer from anxiety. These symptoms 
tend to persist and strongly predict maternal 
depression and anxiety disorders post-
partum,5–9 adversely affecting caregiving.10–14
Along with significant human and economic 
costs to mothers,2 prenatal CMDs are asso-
ciated with poor pregnancy outcomes15–18 
and long- term cognitive and developmental 
problems in offspring.2 18–23 Thus, preventive 
efforts targeting CMDs early in the prenatal 
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Figure 1 Conceptual model of the Happy Mother–Healthy Baby Study. CMD, common mental health disorder; LBW, low birth 
weight; PTB, preterm birth; SGA, small- for- gestational age
period have enormous potential for reducing the nega-
tive effects of postpartum mental disorders on mothers 
and improving child outcomes. In LMICs, a striking gap 
exists between mental health needs and access to care.24 25 
At the same time, no current prevention interventions 
address prenatal anxiety in these settings. Its high prev-
alence, coupled with limited resources for treatment, 
results in an urgent need to expand the evidence base for 
preventive strategies.
While prenatal depression has been the focus of most 
research on CMD in pregnancy to date, anxiety and 
depression often co- occur,26 and prenatal anxiety (espe-
cially occurring early in pregnancy) has been relatively 
neglected. Exposure to anxiety, even as early as during 
the second trimester of pregnancy, is important to intra-
uterine fetal growth.27 28 Given the high prevalence of 
adverse birth outcomes in Pakistan (eg, 47% are born 
small- for- gestational age (SGA)),29 this setting provides 
a unique research opportunity. Due to a paucity of non- 
pharmaceutical initiatives to address anxiety during 
pregnancy, our proposed intervention engages non- 
specialist providers to target symptoms of anxiety using 
strategies based on cognitive–behavioral therapy (CBT). 
CBT is known to effectively treat CMDs30–32 but has been 
underused for prevention in both high- income and low- 
income countries despite evidence- based recommen-
dations.33 As both clinical and subthreshold prenatal 
anxiety strongly predict postpartum depression,6 7 
anxiety- focused interventions may have carry- over bene-
fits on both depression as well as anxiety in the post-
partum period. By creating and testing an intervention to 
be initiated in the first half of pregnancy, we will provide 
critically needed evidence on the effectiveness of these 
approaches to reduce the prevalence of both of these 
damaging maternal conditions and prevent their collat-
eral effects on newborns. Specifically, we aim to examine 
the effects of the intervention on postpartum CMDs, 
birth outcomes and healthcare utilisation costs.
In this manuscript, we give an overview of the design 
and implementation of this randomised controlled trial 
(RCT) with the goal of describing its aims, recruitment, 
randomisation, intervention delivery procedures and 
analysis plan.
MEthoDS AnD AnAlySIS
The purpose of this facility- based RCT in Rawalpindi, 
Pakistan, is to evaluate the impact of using an individu-
ally delivered CBT- based approach in a setting with rela-
tively high rates of postpartum CMDs and adverse birth 
outcomes, for example, SGA and preterm birth (PTB). 
By targeting pregnant women with subthreshold anxiety 
while simultaneously including women with high anxiety 
levels, we aim to measure its effectiveness at reducing 
postpartum CMDs, using both diagnostic and symptom 
measures. The primary endpoint of the study is a 6- week 
postpartum evaluation. A secondary aim is to evaluate the 
effect of the intervention on birth outcomes including 
low birth weight (LBW), SGA and PTB. An important 
feature of the study design is that we exclude women with 
a current major depressive episode (MDE) in order to 
gauge the utility of our intervention specifically focused 
on treating prenatal anxiety symptoms. We will implement 
the intervention using female non- specialist providers 
and integrate the programme into a tertiary care setting.
Additional study goals are to examine mediators and 
moderators of the effects of the intervention (eg, to 
examine the role of perceived stress, social support, 
marital relationship and empowerment; figure 1) as 
well as carry out a cost- effectiveness analysis to ascertain 
whether participation results in reductions in healthcare 
usage and costs. We will use the Client Service Receipt 
Inventory (CSRI) at third trimester and at the 6 weeks’ 
postpartum to collect data on the utilisation and costs 
of healthcare and loss of productivity (including that of 
caregivers) from conception to 6- week postnatal. We will 
3Surkan PJ, et al. BMJ Open 2020;10:e037590. doi:10.1136/bmjopen-2020-037590
Open access
Table 1 Description of intervention sessions
Sessions Content Timing Recipients
1: Psychoeducation and 
stress management
Psychoeducation (information about anxiety and stress 
management skills)
Weekly Intervention 
participants and 
family members
2: Personal well- being Thought challenging and behaviour activation (strategies for 
improving overall well- being, including diet, rest, relaxation, 
sleep and managing common problems during pregnancy)
Weekly Intervention 
participants
3: Social support Thought challenging and behaviour activation (strategies for 
improving interpersonal relationships and social support).
Weekly Intervention 
participants and 
family members
4: Bonding with the infant 
during pregnancy
Thought challenging and behaviour activation (strategies for 
improving bonding with the infant during pregnancy).
Addressing fear of childbirth (knowledge and planning for a 
safe delivery).
Weekly Intervention 
participants
5: Staying well Relapse prevention (problem management strategies to 
prevent relapse).
Weekly Intervention 
participants
Booster sessions: (2–6 
depending on time of 
enrolment)
Behaviour activation and problem management skills Coordinated 
with routine 
antenatal 
visits.
Intervention 
participants
6: Preparing for the baby and 
the early postpartum period
Addressing fear of childbirth (strategies to plan for the baby’s 
arrival).
Psychoeducation (coping with early post- pregnancy 
challenges).
Late 
pregnancy
Intervention 
participants and 
family members
collect information about service utilisation and the out- 
of- pocket expenditures of the participants and the infants, 
including costs for seeing a doctor or other healthcare 
providers, admission to the hospital, medicines, tests and 
extra help at home. The CSRI has been used in Pakistan, 
and an adapted version will be used based on an interna-
tional study on perinatal depression.34
Study overview
Happy Mother, Healthy Baby (HMHB) is a phase three, two- 
arm, single- blind, individual randomised clinical trial 
conducted in the outpatient department of Holy Family 
Hospital (HFH), a large public tertiary care facility affili-
ated with Rawalpindi Medical University (RMU).
HMHB is a psychosocial intervention based on CBT 
for expectant women experiencing anxiety during early 
pregnancy to mid pregnancy. It draws on the core prin-
ciples and strategies of the Thinking Healthy Program, 
an evidence- based psychosocial intervention for mothers 
experiencing perinatal depression, including psycho-
education, empathetic listening, thought challenging, 
behaviour activation, family involvement and problem 
management.35 36 Our formative qualitative research 
immediately prior to the trial indicated the following 
risk factors for anxiety: adverse life events, interpersonal 
problems, lack of support, financial problems, lack of 
appropriate healthcare, gender preference, pregnancy 
complications and fear of labour (see Atif et al37 for 
details). These risk factors are consistent with evidence 
from other studies conducted in Pakistan.9 38–40
The intervention is tailored to address risk factors 
specific to anxiety during pregnancy that were identified 
in our formative research. It additionally incorporates 
stress management skills such as breathing exercises. 
Culturally relevant customised illustrations are used for 
guided discovery, behaviour activation, stress management 
and conveying key health messages. The intervention is 
a series of 5- weekly one- on- one sessions in early to mid 
pregnancy complemented by take- home exercisestable 1. 
These are accompanied by a final sixth therapy session in 
the third trimester of pregnancy, with between two and 
six complementary booster sessions occurring before the 
final core session in the third trimester (table 1). These 
visits are coordinated with women’s routine hospital 
appointments when possible. The number of booster 
sessions will depend on the women’s need for additional 
psychological care and how many additional sessions are 
possible given her date of enrolment in this study.
Women randomised to the control group will receive 
enhanced usual care (EUC). WHO recommends eight 
prenatal visits for positive pregnancy experience,41 which 
is the target number of visits for study participants in 
the EUC control group (depending on their gestational 
week at enrolment). These visits will involve evaluating 
health status, discussing any concerns and performing 
routine examinations consistent with the stage of preg-
nancy (table 2). Usual care will also be enhanced by 
medical staff at the hospital receiving additional training 
from the depression module of Mental Health Gap 
Action Program42 for mental health treatment. Other 
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Table 2 Description of enhanced usual care
Visit Content Timing* Recipients
1 Assessment for anaemia; dietary counselling about healthy eating and keeping 
physically active during pregnancy; folic acid supplements; counselling for 
common physiological symptoms; emphasis on eight antenatal care visits
Following 
recruitment
Intervention 
and control 
participants
2 Same as visit 1, plus iron supplementation Second trimester Same as above
3 Same as visit 1, plus iron supplementation Second trimester Same as above
4 Same as visit 1, plus iron supplementation Third trimester Same as above
5 Same as visit 1, plus iron supplementation Third trimester Same as above
6 Same as visit 1, plus iron supplementation Third trimester Same as above
7 Same as visit 1, plus iron supplementation and tetanus vaccination. Third trimester Same as above
8 Same as visit 1, plus iron supplementation and tetanus vaccination. Third trimester Same as above
Ultrasounds will likely be given on 2–3 of these visits, but may be performed at more visits if medically indicated. The timing will be 
determined by the woman’s obstetrician/gynaecologist.
*These correspond to WHO recommended visits.
enhancements to improve adherence to the intervention 
protocol in both groups include receipt of reimburse-
ments for transportation and for as many ultrasounds as 
are medically indicated at HFH during pregnancy.
Partial patient involvement
Patients were involved in the study through their partic-
ipation in qualitative formative research to inform the 
design of the intervention.37 Through a series of inter-
views with 19 pregnant women at HFH, we asked for their 
input regarding sources of anxiety and manifestations of 
anxiety that were addressed in the curriculum. We also 
incorporated anxious pregnant women’s input regarding 
the most acceptable and culturally appropriate methods 
for delivery of the intervention. As part of their training, 
six therapists piloted the six core intervention sessions 
with 15 pregnant women who fulfilled the study’s eligi-
bility criteria. Of these women, five took part in a qualita-
tive focus group in which they provided input, including 
about the burden of the intervention.
Enrolment and randomisation
Recruitment
Recruitment is carried out by a female assessment team 
based in the outpatient department that describes and 
explains the ‘HMHB study’ to all pregnant women who 
fulfil the initial screening criteria (eg, gestational age, 
language, intent to reside in the area) and their families 
visiting the Gynecology and Obstetrics Department. Preg-
nant women and families who express interest in partici-
pation are invited to be screened for eligibility.
Screening procedure
Research assistants screen all pregnant women who 
register at the Gynecology and Obstetrics Department 
within outpatient services at HFH. We are using three 
levels of inclusion/exclusion screening criteria that occur 
during the same time point at enrolment (figures 2 and 
3). For level 1 screening, we determine if the woman 
is at ≤22 gestational weeks of pregnancy, age ≥18 years 
old, resides ≤20 km from HFH and understands Urdu. If 
fulfilling these criteria, women expressing initial interest 
are asked to provide informed consent for completing 
the next stage of screening (online supplementary file 
1). At level 2 screening, we ascertain if women have (1) 
life- threatening health conditions including active severe 
depression or suicidal ideation, (2) self- report of past or 
current significant learning disability, (3) self- report of 
past or current psychiatric disorder (eg, bipolar disorder 
or schizophrenia) or psychiatric care (eg, current use 
of anxiolytic drug and/or other psychotropic drug), 
(4) medical disorders or severe maternal morbidity that 
require inpatient management that would preclude 
participation or (5) intensive care unit admission (not 
only for assessment). Finally, if not excluded on this basis, 
potential participants will undergo level 3 screening, 
which includes assessment for at least mild anxiety on the 
HADS anxiety questions (ie, score ≥8) and absence of a 
current MDE diagnosis on the Structured Clinical Inter-
view for DSM Disorders (SCID). A full SCID interview 
is only performed on women scoring ≥8 on the HADS 
depression questions.
randomisation
A random sequence of assignments to the study arms was 
generated using a pseudo random- number generator 
and constructed using randomly permuted blocks of size 
4, 8, 12 and 16 by the trial statistician. The assignment 
list was printed in order, with each step of the sequence 
separately stored in opaque envelopes and numbered 
sequentially with a seven- digit code. When an eligible 
woman subsequently provides consent for study partici-
pation (online supplementary file 2), the next available 
envelope is pulled and opened, and assignment to inter-
vention or control is recorded.
The assessment team, trial statistician, principal inves-
tigator and site principal investigators are masked to 
the allocation status of study participants. To maintain 
masking during the trial, intervention and assessment 
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Figure 2 Screening for eligibility or exclusion and baseline assessments.
teams are stationed at separate locations within the HFH 
Gynecology and Obstetrics Department and do not 
interact during the trial. Participants are also instructed to 
not disclose which type of treatment they are receiving to 
the assessment team. Fidelity of masking will be measured 
by having assessors guess the trial arm of each participant 
at the end of follow- up assessment. We hypothesise that 
assessors will only be able to correctly guess the condition 
of participants at a chance rate of around 50%, indicating 
that masking is maintained.
training and supervision of hMhb therapists
HMHB therapists each have a Bachelor’s degree in the 
social sciences and at least 1 year experience of delivering 
maternal psychosocial interventions in low- resource 
settings. Prior to the trial, therapists received 42 hours 
of classroom training (including presentations, discus-
sions and group activities) delivered by the lead trainer, 
followed by 2 months of field training. Classroom training 
focused on understanding anxiety disorder and its 
impact, use of counselling skills to engage participants, 
the CBT approach for overcoming anxiety in conjunction 
with the content and delivery mechanisms of HMHB, and 
detection and reporting of adverse events. Throughout 
the training, HMHB therapists were assessed on knowl-
edge and skills required to deliver the intervention using 
role- playing exercises.
Following the classroom training, all therapists received 
2 months of field training to acquire firsthand experi-
ence delivering the intervention (under supervision of 
the master trainer), to at least two expectant women who 
fulfilled study inclusion criteria. During the field training, 
therapists delivered the six core sessions to the expectant 
women.
One- day required refresher trainings will be conducted 
by the lead trainer twice per year. Refresher training will 
focus on reviewing content and delivery mechanisms of 
HMHB and ensuring that therapists retain their competen-
cies, which will be assessed via role- playing exercises.
Supervision of hMhb therapists
The therapists received weekly group supervision during 
the pilot phase and continue to receive this supervi-
sion during the trial. This supervision is conducted by a 
psychologist (lead trainer, coinvestigator on this study) in 
order to provide ongoing support and guidance. Super-
vision is conducted in- person and online (using online 
video conferencing software, like Skype).
Assessment of hMhb therapist competence
To ensure the quality of the intervention and competency 
of the therapists to provide it, assessments were carried 
out throughout the training and continue into the trial 
period. All therapists are evaluated on their knowledge of 
the intervention (eg, strategies, procedures) and specific 
skills required to deliver it. These skills are assessed using 
an adapted version of the ENhancing Assessment of 
Common Therapeutic factors (ENACT) rating scale43 to 
facilitate rating therapist competence. These assessments 
will ensure that the intervention is delivered with high 
enough quality to achieve the expected effects, that all the 
intervention contents are delivered with fidelity, and that 
the specific skills required for its delivery are maintained.
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Figure 3 Randomisation and follow- up assessment flow diagram. DHS, Demographic Health Survey; GAD, generalised 
anxiety disorder; HADS, Hospital Anxiety and Depression Scale; HMHB, Happy Mother, Healthy Baby; IPV, intimate partner 
violence; LBW, low birth weight; MDE, major depressive episode; MRQ, MacArthur Relationship Questionnaire; MUAC, mid- 
upper arm circumference; MSPSS, Multidimensional Scale of Perceived Social Support; PAAS, Premium Abbreviated Activation 
Scale; PES- Brief, Pregnancy Experience Scale- Brief; PSS-10, Perceived Stress Scale; PTB, preterm birth; SCID, Structured 
Clinical Interview for DSM Disorders; SGA, small- for- gestational age; WHODAS 2.0, WHO Disability Assessment Schedule.
During the classroom training and refresher training 
sessions, assessments will be conducted via role- playing 
exercises. The therapists will be given different scenarios 
for role- playing exercises, which are assessed by the lead 
trainer and other HMHB therapists. During the field 
training, an independent assessor (ie, research assistants 
who received full HMHB training as well as training 
on assessment using the adapted ENACT rating scale) 
7Surkan PJ, et al. BMJ Open 2020;10:e037590. doi:10.1136/bmjopen-2020-037590
Open access
observed two randomly selected sessions conducted by 
each therapist. ‘Independent’ assessors are research team 
members not involved in delivering the training or inter-
vention and therefore can conduct unbiased assessments. 
Therapists are also not involved in selection of the sessions 
to be rated. The independent assessor reports the results 
of the evaluation to the supervisor (master trainer), who 
provides feedback to the therapist. Over the duration of 
the trial, an independent assessor will randomly observe 
15% of the core sessions (240 sessions) delivered to the 
participants. The participants are asked permission for 
the session to be observed, and on receiving permission, 
an independent assessor evaluates the session and shares 
the outcome with the supervisor.
Data collection
Data are being collected at four time points: baseline (at 
enrolment), in the third trimester, at birth and at 6- week 
postpartum (see figure 2). Data collection is coordinated 
with patients’ scheduled prenatal visits when possible 
and takes place at the hospital for the baseline and third 
trimester visit. Data on birth outcomes are collected via 
medical records. The final postpartum follow- up will be 
conducted in the woman’s home.
Quantitative endpoints and data analysis
Our primary endpoint is diagnosis of CMDs, namely 
generalised anxiety disorder (GAD) and MDE, as assessed 
by the SCID at 6- week postpartum. We hypothesise that 
randomisation of women with subclinical to clinical levels 
of prenatal anxiety to the intervention arm will result in 
fewer cases of CMDs at 6- week postpartum compared with 
the control arm of mothers with similar levels of baseline 
anxiety who do not receive the intervention. We will also 
assess women’s symptoms of anxiety and depression as 
endpoints.
Our secondary outcomes include birth outcomes; we 
hypothesise that randomisation of women with subclin-
ical to clinical levels of prenatal anxiety to the interven-
tion will improve these outcomes, that is, reduce the 
likelihood of growth restriction (SGA), LBW and PTB.
Sample size determination
In our study, the unit of randomisation is an individual 
woman, with an equal number of women randomised to 
the intervention and control groups. We assumed a signif-
icance level of 0.05. Sample size calculations were based 
on χ2 tests comparing outcome rates in the intervention 
and control groups. We assumed an outcome prevalence 
of CMDs (MDE and GAD) at 30%, which we considered 
conservative given that most estimates of prenatal depres-
sion in Pakistan are higher than this.3 4 39 44 Assuming this 
prevalence and considering a 30% reduction in CMDs as 
meaningful,1 45 46 we will need to measure this outcome in 
840 pregnant women (420 in each arm) to achieve 85% 
power. Based on our prior research experience in Pakistan, 
we will overenrol to compensate for 30% attrition post 
enrolment; this attrition rate will require us to enrol 600 
women per group in this study, for a total of 1200 women.
This sample size of 420 outcomes per group provides 
ample power to detect important reductions in SGA, which 
we currently estimate to occur in approximately 47% of 
births. For example, we will have 90% and 80% power to 
detect reductions in SGA incidence of 23.7% and 20.2%, 
respectively. With the sample size of 420 per group, we will 
have about 85% power to detect a 21.6% relative reduction 
in SGA, if SGA in the population is 47%.
Data management
Data from participants as well as evaluations of thera-
pists are being collected using the Open Data Kit (ODK) 
platform on password protected tablets. In preparation 
for the trial, a full- day workshop was conducted by the 
study’s data manager for training on the use of ODK. A 
running audit trail is being maintained, in which data are 
continuously evaluated for outliers by the data collection 
team and trial statistician. ODK forms, which include all 
measures assessed including ENACT, are designed to 
autosave and are sent to the server via the internet at the 
end of each working day, after which all they are erased 
from the tablets on which the data are collected. Daily 
backups are made on a personal computer and the cloud, 
and weekly backups are made on a password- protected 
local portable hard drive. The data manager shares a 
weekly report with investigators in the US and Pakistan 
including an enrolment table with screening details of 
the trial participants, information about dropout and 
any adverse events. Data cleaning takes place at the end 
of each day. The data manager uses the women’s last 
menstrual period recorded at screening to predict the 
start of third trimester and generate follow- up lists for 
the sixth required study visit to take place in the third 
trimester.
Statistical analyses
Initial analyses will compare baseline characteristics of 
research participants between the two study arms; partic-
ipants who completed follow- up assessments and partic-
ipants who could not complete follow- up assessments; 
and the distribution of potential confounding factors. 
Findings will be reported as per Consolidated Standards 
of Reporting Trials guidelines for RCTs including a trial 
flow chart. This will include the flow of participants 
through each stage of the trial, including the number 
eligible, randomly assigned, receiving the intended treat-
ment, completing the study protocol and analysed for the 
primary outcome.
The outcome measures will be summarised at baseline 
and follow- up, both overall and by intervention arm. These 
will be summarised by means (SD), medians (IQR) or 
numbers and proportions as appropriate. For continuous 
outcomes, histograms within each arm will be plotted to 
assess how closely the scales follow a normal distribution 
and to determine how to describe the outcomes and how 
to properly perform the inferential analysis.
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Analysis of the primary efficacy endpoint
The primary outcome of the study is the prevalence of 
cases of CMDs (GAD and MDE) in both study arms. Diag-
nosed cases of both GAD and MDE will be assessed with 
the SCID.
All randomised participants for whom we have outcome 
data will be included in the intention- to- treat analysis. The 
intervention group (enrolled after being screened for 
subclinical or clinical levels of anxiety) will be compared 
with non- intervention controls (selected on the same 
criteria) to examine the effects of the intervention on 
development of CMDs. The primary analysis will involve 
outcome assessment in the mothers randomly assigned 
to the two conditions using Fisher’s exact test. Primary 
analyses will include direct estimation of the change 
in mean estimate and/or relative risk of the outcomes 
along with the 95% CI around that outcome using linear 
and Poisson regression to control for baseline maternal 
characteristics.47 Other sensitivity analyses may evaluate 
whether there was more of an effect among women who 
received the full intervention. Variable transformations 
(such as square root or log) will be used as appropriate to 
meet the model assumptions.
Analysis of secondary endpoints
We will secondarily compare the intervention and 
control groups in terms of changes in CMD symptom 
scores, by measuring depressive symptoms with the 
nine- item Patient Health Questionnaire and the HADS 
anxiety questionnaire. Other variables of interest, but 
not primary targets, include birth outcomes (SGA, LBW 
and PTB), perceived stress (using the Perceived Stress 
Scale), pregnancy- related anxiety (using the Pregnancy 
Experience Scale (PES- Brief)), maternal functioning 
(using WHO Disability Assessment Schedule), marital 
relationships (using the MacArthur Relationship Ques-
tionnaire), intimate partner violence, women’s empow-
erment, maternal bonding, maternal responsiveness, 
child growth at 6- week postpartum, as well as initiation 
and exclusivity of breast feeding (WHO measures). 
Pregnancy- related symptoms of anxiety (measured with 
the PES- Brief) will be assessed at baseline and in the 
third trimester.
For secondary outcomes not related to mental health, 
we will estimate the effects of the intervention using birth 
and follow- up (6- week postpartum) measures separately. 
Main analyses will performed with non- parametric tests, 
by comparing pre- to post- tests in women randomly 
assigned to the two conditions; however, sensitivity anal-
yses will use parametric models such as linear and logistic 
regression to control for baseline values of maternal char-
acteristics.47 Variable transformations (such as square 
root or log) will be used as appropriate to meet the model 
assumptions. For primary and secondary endpoints, in all 
regression models, the coefficient of the HMHB versus 
non- HMHB (control group) indicator variable will be 
taken as the estimated effect.
Economic analysis
The data collected through the CSRI will be used to 
calculate service costs and total costs of care for each 
participant. Unit costs of services itemised in the CSRI—
such as cost per outpatient visit—will be based on locally 
conducted health facility costing exercises. Service cost 
data will subsequently be linked to primary and secondary 
study outcomes to assess issues around the value or cost 
effectiveness of the task- shifting intervention. In the 
event that dominance is not shown, that is, the interven-
tion is more effective but the costs in the intervention 
group are also more than in the EUC group, incremental 
cost- effectiveness ratios will be computed, together with 
their CIs (using bootstrapping techniques to overcome 
the expected skewness of the cost data). Results will be 
plotted on a cost- effectiveness plane and presented as 
cost- effectiveness acceptability curves to show the prob-
ability of the intervention being cost effective at a range 
of willingness- to- pay threshold levels. A sensitivity analysis 
will be conducted to take into account uncertainty and 
imprecision in the measurements, including multiple 
imputation models for missing values.
Missing data
Adjusted analysis and subgroup analysis will be based 
on covariates at baseline with non- missing values. Sensi-
tivity analysis will be performed on the covariates with 
imputed missing values.48 All analyses will be detailed in 
the statistical analysis plan, which will be finalised before 
unblinding the study.
Qualitative process evaluation
To supplement our quantitative data analysis, we will 
collect qualitative data from approximately 20 women in 
the intervention group and 10 women in the EUC group 
(or until saturation is achieved) to gain an in- depth 
understanding of the women’s experiences with the 
programme (including opportunity/emotional costs of 
participation). These women will be purposively sampled 
to achieve a wide range of variation (or maximum vari-
ation) on dimensions of interest (eg, type of stressor 
identified in the intervention, age, number of prior preg-
nancies, HADS score). To triangulate and learn from 
multiple perspectives, we will also hold one focus group 
discussion with the HMHB therapists.
Ethics
This study was reviewed and approved by the Johns 
Hopkins Bloomberg School of Health (JHSPH) Insti-
tutional Review Board (Baltimore, USA), the Human 
Development Research Foundation Ethics Committee 
(Islamabad, Pakistan), the RMU Institutional Research 
Forum (Rawalpindi, Pakistan) and the National Insti-
tute of Mental Health (NIMH) appointed Global Mental 
Health Data Safety and Monitoring Board (DSMB).
Women are discontinued from the study in the case of 
stillbirth or infant death prior to the final assessment at 
9Surkan PJ, et al. BMJ Open 2020;10:e037590. doi:10.1136/bmjopen-2020-037590
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6- week postpartum or on request of the participant. No 
interim analyses or stopping rules are planned.
This study is monitored with oversight by the NIMH 
DSMB. The committee meets twice a year and is composed 
of senior global mental health professionals. Detailed 
reports are sent to the DSMB triannually, including 
reports on any adverse events. Progress reports are sent 
to the JHSPH on an annual basis.
DISSEMInAtIon
The HMHB Trial is designed to reduce symptoms of 
anxiety during pregnancy, which has the potential to 
impact development of maternal postpartum CMDs, 
including postpartum depression and anxiety as well as 
intrauterine growth, reflected in SGA, LBW and PTB. 
Additional findings from this study will describe the 
mechanism through which the intervention may be oper-
ating, particular subgroups for whom the intervention 
may be more beneficial, as well cost effectiveness of the 
intervention in terms of costs to both the women and the 
health system.
The principal investigator and coinvestigators both 
in the USA and the host country will be given access to 
the cleaned data sets. Deidentified project data from the 
study will be posted on  clinicaltrials. gov and the NIMH 
data archive. Study results will be disseminated through 
peer- reviewed journals and conferences. Data collection 
for the trial started on April 16, 2019 and will continue 
until September 2021.
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